Holen Sie sich die Stockscreener-App
2.3999
2.63%
-0.0701
Schlusskurs vom Vortag:
$2.47
Offen:
$2.56
24-Stunden-Volumen:
3.72M
Relative Volume:
0.76
Marktkapitalisierung:
$538.23M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-1.132
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
+4.57%
1M Leistung:
+33.61%
6M Leistung:
+112.83%
1J Leistung:
+27.25%
1-Tages-Spanne:
$2.36
$2.73
1-Wochen-Bereich:
$2.21
$2.73
52-Wochen-Spanne:
$0.8621
$2.80
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.395 | 555.08M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.45 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.75 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.81 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - Zacks Investment Research
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus
Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlight - GuruFocus
Allogene Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast - Investing.com South Africa
Rate Cut: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
Allogene (ALLO) Q4 2025 Earnings Call Transcript - The Globe and Mail
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts - ChartMill
Allogene Therapeutics: Fourth Quarter Earnings Overview - Bitget
Allogene Therapeutics 2025 10-K: Net loss $190.9M, EPS $(0.87); runway into Q1 2028 - TradingView
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Bitget
Allogene Therapeutics: Q4 Earnings Snapshot - WWLTV.com
Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway - Stock Titan
Cancer and autoimmune push: inside Allogene’s 2026 CAR T trials - Stock Titan
Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease - Traders Union
Aug Shorts: What are the future prospects of Allogene Therapeutics IncAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Allogene Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - TradingView
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday - MarketBeat
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance
Allogene at TD Cowen Conference: Strategic Cell Therapy Insights By Investing.com - Investing.com Canada
ALLO: Key clinical milestones and manufacturing advances position allogeneic cell therapy for broad impact - TradingView
Allogene Therapeutics (NASDAQ: ALLO) files Form 144 for 7,132 RSU shares - Stock Titan
Allogene Therapeutics signals breakthrough hope for severe autoimmune disease patients - Traders Union
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewswire
Ideas Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
ALLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year HighHere's What Happened - MarketBeat
FOMO Trade: Is Allogene Therapeutics Inc.’s ROE strong enoughGold Moves & Weekly Breakout Watchlists - mfd.ru
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%Should You Buy? - MarketBeat
Allogene Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Allogene Therapeutics, Inc. $ALLO Shares Acquired by Aberdeen Group plc - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Raised to "Hold" at Wall Street Zen - MarketBeat
Treasury Yields: Whats the fair value of Blend Labs Inc stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Allogene Therapeutics Faces Financial Challenges Despite Industry Moves - StocksToTrade
Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission - Yahoo Finance
MSN Money - MSN
ALLO: ALPHA-3 aims for a 25%-30% MRD clearance improvement in lymphoma, with pivotal data due in April - TradingView
Arie Belldegrun details 5.8% Allogene (ALLO) stake via multiple entities - Stock Titan
Allogene Therapeutics unveils plans for Virtual Oncology Summit - Traders Union
Atomera Among 3 Promising Penny Stocks - simplywall.st
Will Allogene Therapeutics Inc. stock outperform value stocks2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen - MarketBeat
Will Allogene Therapeutics Inc. benefit from geopolitical trendsQuarterly Portfolio Report & Fast Entry Momentum Alerts - mfd.ru
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):